Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0001193125-20-176446 0001813314 XXXXXXXX LIVE 6 Common Stock, par value $0.0001 per share 04/16/2026 false 0001763950 51654W101 Lantern Pharma Inc. 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 Bios Equity Partners, LP 817-984-9197 1751 River Run Suite 400 Fort Worth TX 76107 0001813314 N Bios Equity Partners, LP b AF N TX 0.00 420802.00 0.00 420802.00 420802.00 N 3.7 PN Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, and (iii) 26,093 Shares directly held by BP Directors. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001789490 N Fletcher Aaron G.L. b AF N X1 0.00 834752.00 0.00 834752.00 834752.00 N 7.4 IN Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001813844 N BIOS Advisors GP, LLC b AF N TX 0.00 834752.00 0.00 834752.00 834752.00 N 7.4 PN Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001813845 N BIOS Capital Management, LP b AF N TX 0.00 834752.00 0.00 834752.00 834752.00 N 7.4 PN Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Bios Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001813313 N Bios Equity Partners II, LP b AF N TX 0.00 413950.00 0.00 413950.00 413950.00 N 3.7 PN Shared voting and dispositive power consists of (i) 88,029 Shares directly held by Bios Fund II, (ii) 287,442 Shares directly held by Bios Fund II QP and (iii) 38,479 Shares directly held by Bios Fund II NT. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001714576 N BIOS Fund II, LP b WC N DE 0.00 88029.00 0.00 88029.00 88029.00 N 0.8 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund II, LP ("Bios Fund II"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001728851 N BIOS Fund II NT, LP b WC N DE 0.00 38479.00 0.00 38479.00 38479.00 N 0.3 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001716869 N BIOS Fund II QP, LP b WC N DE 0.00 287442.00 0.00 287442.00 287442.00 N 2.6 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001697316 N BIOS Fund I, LP b WC N DE 0.00 249037.00 0.00 249037.00 249037.00 N 2.2 PN Shared voting and dispositive power consists of shares of common stock, par value $0.0001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001700297 N BIOS Fund I QP, LP b WC N DE 0.00 145672.00 0.00 145672.00 145672.00 N 1.3 PN Shared voting and dispositive power consists of Shares directly held by Bios Fund I QP, LP ("Bios Fund I QP"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001813311 N BP Directors, LP b OO N DE 0.00 26093.00 0.00 26093.00 26093.00 N 0.2 PN Shared voting and dispositive power consists of Shares directly held by BP Directors, LP ("BP Directors"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001813310 N Cavu Advisors, LLC b AF N TX 0.00 834752.00 0.00 834752.00 834752.00 N 7.4 PN Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management, and therefore may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001813270 N Cavu Management, LP b AF N TX 0.00 834752.00 0.00 834752.00 834752.00 N 7.4 PN Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. 0001813316 N Kreis Leslie W. b AF OO N X1 0.00 834752.00 0.00 834752.00 834752.00 N 7.4 IN Shared voting and dispositive power consists of (i) 249,037 Shares directly held by Bios Fund I, (ii) 145,672 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 88,029 Shares directly held by Bios Fund II, (v) 287,442 Shares directly held by Bios Fund II QP and (vi) 38,479 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities. Percentage based on 11,254,697 outstanding Shares as reported in the Form 10-Q filed by the Issuer on March 16, 2026. Common Stock, par value $0.0001 per share Lantern Pharma Inc. 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 This Amendment No. 6 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on June 15, 2020 (the "Original Schedule 13D"), as amended by the statement on Schedule 13D/A filed with the Commission on March 22, 2022 ("Amendment No. 1"), as further amended by the statements on Schedule 13D/A filed with the Commission on December 1, 2023 ("Amendment No. 2"), March 1, 2024 ("Amendment No. 3"), June 12, 2025 ("Amendment No. 4"), February 23, 2026 ("Amendment No. 5"), and, together with the Original Schedule 13D, Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4, and Amendment No. 5, the "Prior Statements"). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the "Shares"), of Lantern Pharma, Inc., a Delaware corporation (the "Issuer"). The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. The information contained on the cover pages of this Schedule 13D is incorporated herein by reference. Except as described in this Amendment No. 6, to the knowledge of the Reporting Persons, only the Reporting Persons have the right to receive or the power to direct receipt of dividends from, or proceeds from the sale of, the Shares reported by the Schedule 13D. Not applicable Exhibit 99.1: Joint Filing Agreement, dated June 23, 2020 (incorporated by reference to the Original Schedule 13D, filed on June 23, 2020). Bios Equity Partners, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 Fletcher Aaron G.L. /s/ John Fucci John Fucci, as Attorney-in-Fact for Aaron G.L. Fletcher 04/16/2026 BIOS Advisors GP, LLC /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 BIOS Capital Management, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 Bios Equity Partners II, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 BIOS Fund II, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 BIOS Fund II NT, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 BIOS Fund II QP, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 BIOS Fund I, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 BIOS Fund I QP, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 BP Directors, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 Cavu Advisors, LLC /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 Cavu Management, LP /s/ John Fucci John Fucci/Attorney-in-Fact 04/16/2026 Kreis Leslie W. /s/ John Fucci John Fucci, as Attorney-in-Fact for Leslie W. Kreis, Jr. 04/16/2026 BIOS FUND II, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND II QP, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND II NT, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorneyin-Fact BIOS INCYSUS CO-INVEST I, LP By: Bios Equity Partners II, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND III, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND III QP, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS FUND III NT, LP By: Bios Equity Partners III, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS CLINICAL OPPORTUNITY FUND, LP By: Bios Equity COF, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner BP DIRECTORS, LP By: Bios Equity Partners, LP, its general partner By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS EQUITY PARTNERS II, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in Fact BIOS EQUITY PARTNERS III, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner By: /s/ John Fucci John Fucci Attorney-in-Fact BIOS EQUITY COF, LP By: Bios Capital Management, LP, its general partner By: Bios Advisors GP, LLC, its general partner CAVU MANAGEMENT, LP By: Cavu Advisors, LLC, its general partner By: /s/ John Fucci Attorney-in-Fact BIOS CAPITAL MANAGEMENT, LP By: Bios Advisors GP, LLC its general partner By: /s/ John Fucci Attorney in-Fact